| pubmed-article:10100564 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0038953 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:10100564 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:10100564 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10100564 | pubmed:dateCreated | 1999-6-22 | lld:pubmed |
| pubmed-article:10100564 | pubmed:abstractText | The therapeutic options for patients with acute leukemia who relapse after the initial transplant include second bone marrow transplantation (2BMT) and conventional chemotherapy (CC). In this work, we conducted an analysis of published survival data and we evaluated the cost-effectiveness of 2BMT in comparison with CC. We retrieved survival information on 167 patients treated with 2BMT and 299 patients treated with CC. Survival figures were derived from individual patient data and were compared between 2BMT and CC. The mean lifetime survival (MLS) was estimated for each of the two patient cohorts using standard techniques of survival-curve extrapolation. The cost data of patients given 2BMT or CC were estimated from published data. Our analysis of individual survival data showed that 2BMT improved survival at levels of statistical significance (survival gain = 19.6 months per patient). Using an incremental cost of $90000 per patient, the cost-effectiveness ratio of 2BMT in comparison with CC was calculated as $52215 discounted dollars per discounted life year gained. Our results indicate that, in patients with acute leukemia who relapse after their first transplant, 2BMT significantly prolongs survival in comparison with CC and seems to have an acceptable cost-effectiveness profile. | lld:pubmed |
| pubmed-article:10100564 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10100564 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10100564 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10100564 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10100564 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10100564 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:Van LintM TMT | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:LocatelliFF | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:AmiciAA | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:BosiAA | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:MessoriAA | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:BacciSS | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:LaszloDD | lld:pubmed |
| pubmed-article:10100564 | pubmed:author | pubmed-author:TrippoliSS | lld:pubmed |
| pubmed-article:10100564 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10100564 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:10100564 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10100564 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10100564 | pubmed:pagination | 489-95 | lld:pubmed |
| pubmed-article:10100564 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:meshHeading | pubmed-meshheading:10100564... | lld:pubmed |
| pubmed-article:10100564 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10100564 | pubmed:articleTitle | Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. Gruppo Italiano Trapianto di Midollo Osseo. | lld:pubmed |
| pubmed-article:10100564 | pubmed:affiliation | Laboratorio di Farmacoeconomia, Drug Information Center, Azienda Ospedaliera Careggi, Firenze, Italy. | lld:pubmed |
| pubmed-article:10100564 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10100564 | lld:pubmed |
